Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer

NCT ID: NCT03029533

Last Updated: 2017-01-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-28

Brief Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety of DWJ108J (leuprolide acetate) and Leuplin DPS Inj administered subcutaneously in patients with prostate cancer

Conditions

Prostate Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DWJ108J (leuprolide acetate)

DWJ108J (leuprolide acetate)

Group Type: EXPERIMENTAL

Leuprolide Acetate

Intervention Type: DRUG

DWJ108J, SC injection, once(Day1)

Leuplin DPS Inj

Leuplin DPS Inj

Group Type: ACTIVE_COMPARATOR

Leuprolide Acetate

Intervention Type: DRUG

Leuplin DPS Inj, SC injection, once(Day1)

Interventions

Leuprolide Acetate

DWJ108J, SC injection, once(Day1)

Intervention Type: DRUG

Leuprolide Acetate

Leuplin DPS Inj, SC injection, once(Day1)

Intervention Type: DRUG

Other Intervention Names

DWJ108J; Leuplin DPS Inj

Eligibility Criteria

Inclusion Criteria

1. Males ≥19 and ≤80 years of age at Screening.

2. Subject with histologically proven adenocarcinoma of the prostate requiring androgen deprivation therapy

3. An ECOG performance status grade of 0 to 2,

4. 19kg/m2≤ Body Mass Index (BMI) ≤30kg/m2 at Screening.

Exclusion Criteria

1. Confirmed Hormone refractory prostate cancer(HRPC)

2. Has had history of bilateral orchiectomy, suprarenalectomy or hypophysectomy.

3. Diagnosed pituitary adenoma

4. Has a history of depression

5. Has a risk of spinal cor d compression due to metastatic spinal cord injury.

6. Has a severe urethratresia.

7. Confirmed uncontrolled Congestive heart failure (CHF) within 6 months of Screening.

8. Has a history of MI or any procedure with regard to coronary artery disease within 6 months of Screening. (e.g., balloon angioplasty, coronary artery bypass graft)

9. Has any severe concomitant disease that would interfere with the conduct of the study except for prostate cancer

10. Has allergy history of leuprolide acetate, similar GnRH drugs or other medications (e.g., Aspirin, antibiotics) and/or has any allergic disease requiring treatment.

11. Has received an investigational drug within 9 0days of Screening.

12. Drug releasing is expected after administration of study drug, if subject received GnRH agonist for treatment of prostate cancer.

13. Has other chemotherapy planned within 14weeks from administration of study drug, except for androgen deprivation therapy.

14. Has no willing of using method of contraception throughout the study period.

15. Systolic Blood Pressure < 90mmHg and/or ≥160mmHg or Diastolic Blood Pressure < 60mmHg and/or ≥100mmHg at Screening

16. QTcF >450msec at Screening ECG.

17. HbA1c level is high the upper limit of normal of reference range.

18. Serum AST, ALT or Creatinine > 1.5times the upper limit of normal at Screening.

19. Positive results of tests for hepatitis B, hepatitis C, HIV or syphilis.

20. Has any condition that, in the opinion of the investigator, would make participation not be in the best interest of the subject.

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

DW_LP3M002

Identifier Type: -

Identifier Source: org_study_id